Neuilly sur Seine, France

Michelle Devissague

This inventor holds 1 USPTO granted patent. Top assignee: Adir Et Compagnie. Active years: 1992.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 1992

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michelle Devissague: Innovator in Pharmaceutical Chemistry

Introduction

Michelle Devissague is a prominent inventor based in Neuilly sur Seine, France. She has made significant contributions to the field of pharmaceutical chemistry, particularly through her innovative work on pyrrolo [1,2-a] thieno [3,2-f][1,4]diazepine compounds. Her research focuses on developing compounds that have potential therapeutic applications.

Latest Patents

Michelle holds a patent for her invention titled "Pyrrolo [1,2A] thieno [3,2-F] [1,4] diazepines." This invention relates to pyrrolo [1,2-a] thieno [3,2-f][1,4]diazepine compounds, which are useful for treating various medical conditions such as cerebral ischemia, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, and hyperglycemia. The compounds are synthesized in a few steps from the corresponding substituted 2-(1-pyrrolyl)thiophenes, showcasing her innovative approach to drug development. Michelle has 1 patent to her name.

Career Highlights

Michelle is currently associated with Adir Et Compagnie, where she continues to advance her research in pharmaceutical chemistry. Her work has garnered attention for its potential impact on treating significant health issues.

Collaborations

Throughout her career, Michelle has collaborated with notable colleagues, including Max Robba and Marie P Foloppe. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Michelle Devissague is a trailblazer in the field of pharmaceutical chemistry, with her innovative inventions paving the way for new treatments. Her dedication to research and collaboration highlights her commitment to improving health outcomes through science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…